IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII

The development of inhibitory antibodies to factor VIII (FVIII) is a major obstacle in using this clotting factor to treat individuals with hemophilia A. Patients with a congenital absence of FVIII do not develop central tolerance to FVIII, and therefore, any control of their FVIII-reactive lymphocy...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Clin Invest
Hauptverfasser: Matino, Davide, Gargaro, Marco, Santagostino, Elena, Di Minno, Matteo N.D., Castaman, Giancarlo, Morfini, Massimo, Rocino, Angiola, Mancuso, Maria E., Di Minno, Giovanni, Coppola, Antonio, Talesa, Vincenzo N., Volpi, Claudia, Vacca, Carmine, Orabona, Ciriana, Iannitti, Rossana, Mazzucconi, Maria G., Santoro, Cristina, Tosti, Antonella, Chiappalupi, Sara, Sorci, Guglielmo, Tagariello, Giuseppe, Belvini, Donata, Radossi, Paolo, Landolfi, Raffaele, Fuchs, Dietmar, Boon, Louis, Pirro, Matteo, Marchesini, Emanuela, Grohmann, Ursula, Puccetti, Paolo, Iorio, Alfonso, Fallarino, Francesca
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Clinical Investigation 2015
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4607121/
https://ncbi.nlm.nih.gov/pubmed/26426076
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI81859
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge